Pharmaceutical company Breckenridge Pharmaceutical, Inc., a subsidiary of Towa International, announced on Wednesday that it has received final approval from the US Food and Drug Administration for Methadone Hydrochloride Injection USP, 200mg/20mL (10mg/mL) Multi-Dose Vial.

The product will be launched immediately and is indicated for managing severe, persistent pain requiring extended opioid treatment and for temporary use in opioid dependence when oral medication is not an option.

This launch supports Breckenridge Pharmaceutical's strategy to strengthen its institutional channel presence and diversify its portfolio. Expanding its US offerings to include Oncology, Autoimmune, Rare Disease and Supportive Care products underscores the company's focus on innovation and growth. These initiatives align with Towa International's broader vision of promoting holistic health.